TrialClinical & experimental ophthalmology2021

Intravitreous treatment of severe ocular von Hippel-Lindau disease using a combination of the VEGF inhibitor, ranibizumab and PDGF inhibitor, E10030: Results from a phase 1/2 clinical trial.

Christopher K Hwang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.